# Cytrellis Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytrellis-biosystems

- Industry: Medical Devices & Equipment
- Headquarters: Woburn, US
- Website: www.cytrellis.com
- Total disclosed funding: $86M
- Latest round: Series C (Jun 4, 2021)
- Investors on record: 8

## About

Cytrellis Biosystems, Inc., based in Woburn, US, specializes in developing innovative aesthetic medical devices, particularly the ellacor® system, which employs Micro-Coring® Technology for skin rejuvenation.Founded in 2011 in Woburn, US, Cytrellis Biosystems, Inc. is focused on creating aesthetic medical solutions. The company has secured a total of USD 50 mn in Series C funding, led by D1 Capital Partners, with participation from ARCH Venture Partners, PFM Health Sciences, and Sands Capital Ventures. Its most recent funding round took place on June 4, 2021. Jason Richey and Karen C. are leading the company as CEO.Cytrellis, Inc. specializes in the development and commercialization of innovative aesthetic medical devices, with a primary focus on its flagship product, ellacor®. This proprietary system employs Micro-Coring® Technology to effectively remove sagging skin on a micro-scale, addressing age-related skin changes and enhancing youthful appearance. The ellacor® system is designed for use by aesthetic practitioners, providing them with advanced tools to achieve superior cosmetic results for their clients. The company markets its products primarily to medical professionals in the aesthetic field across various geographical regions, including North America and Europe, positioning itself in a niche market that caters to clinics and practices focusing on skin rejuvenation and cosmetic enhancements.The revenue model for Cytrellis, Inc. is based on direct sales to medical practitioners and aesthetic clinics that utilize its products in their service offerings. Sales transactions occur through partnerships with healthcare facilities, where ellacor® systems are integrated into existing aesthetic treatments. The company engages in B2B transactions, supplying its proprietary devices to clinics that cater to patients seeking skin rejuvenation solutions. Pricing plans for ellacor® and associated services reflect the value provided to practitioners, enabling them to offer enhanced aesthetic procedures to their clientele. This strategic approach supports the business's revenue generation and reinforces the company’s commitment to advancing the aesthetic medical technology landscape.Cytrellis Biosystems, Inc. plans to utilize the USD 50 mn raised in Series C funding to enhance its commercial infrastructure, support clinical research, product development, and manufacturing. The company is focused on expanding into additional markets and geographic regions, particularly in North America and Europe, to broaden its reach. Specific timelines for product launches or detailed market entry strategies have not been disclosed.

## Funding rounds

- Series C, Jun 4, 2021, $50M — ARCH Venture Partners, Sands Capital Alternatives, D1 Capital Partners, PFM Health Sciences
- Series B, Jun 5, 2018, $29M — ARCH Venture Partners, Anteis, Partner Fund Management, Biomatics Capital Partners, Merz Group
- Series A, Feb 9, 2015, $7.1M — ARCH Venture Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Anteis — Series B
- Partner Fund Management — Series B
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series B
- Merz Group — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- D1 Capital Partners (https://capitalatlas.ai/funds/d1-capital-partners) — Series C
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series C